c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity DOI Creative Commons
Parham Jabbarzadeh Kaboli, Ghazaal Roozitalab, Reyhaneh Farghadani

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 27, 2024

Cellular mesenchymal-epithelial transition factor (c-MET), also known as hepatocyte growth receptor (HGFR), is a crucial tyrosine kinase implicated in various solid tumors, including lung, breast, and liver cancers. The concomitant expression of c-MET PD-L1 such hepatocellular carcinoma, highlights their prognostic significance connection to therapeutic resistance. Cancer-associated fibroblasts mesenchymal stromal cells produce (HGF), activating signaling tumor myeloid-derived suppressor (MDSC). This activation leads metabolic reprogramming increased activity enzymes like glutaminase (GLS), indoleamine 2,3-dioxygenase (IDO), arginase 1 (ARG1), depleting essential amino acids the microenvironment that are vital for effector immune cell function. review interplay between (MDSCs) create an immunosuppressive environment while providing targets c-MET-focused immunotherapy. It emphasizes clinical implications inhibition on behavior neutrophils, macrophages, T cells, NK cells. explores potential antagonism combined with immunotherapeutic strategies enhance cancer treatment paradigms. discusses innovative immunotherapies targeting c-MET, chimeric antigen (CAR) therapies, monoclonal antibodies, antibody-drug conjugates, encouraging development comprehensive strategy simultaneously tackles evasion enhances anti-tumor efficacy further improve prognoses patients c-MET-positive malignancies. Despite challenges variability across different subtypes, continued research into molecular mechanisms will be crucial.

Language: Английский

Novel benzofuran-conjugated indolin-2-ones as anticancer agents; design, synthesis, biological assessments, and molecular modeling insights DOI
Wagdy M. Eldehna, Haytham O. Tawfik, Mohamed S. Nafie

et al.

Bioorganic Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 108494 - 108494

Published: April 1, 2025

Language: Английский

Citations

0
c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity DOI Creative Commons
Parham Jabbarzadeh Kaboli, Ghazaal Roozitalab, Reyhaneh Farghadani

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 27, 2024

Cellular mesenchymal-epithelial transition factor (c-MET), also known as hepatocyte growth receptor (HGFR), is a crucial tyrosine kinase implicated in various solid tumors, including lung, breast, and liver cancers. The concomitant expression of c-MET PD-L1 such hepatocellular carcinoma, highlights their prognostic significance connection to therapeutic resistance. Cancer-associated fibroblasts mesenchymal stromal cells produce (HGF), activating signaling tumor myeloid-derived suppressor (MDSC). This activation leads metabolic reprogramming increased activity enzymes like glutaminase (GLS), indoleamine 2,3-dioxygenase (IDO), arginase 1 (ARG1), depleting essential amino acids the microenvironment that are vital for effector immune cell function. review interplay between (MDSCs) create an immunosuppressive environment while providing targets c-MET-focused immunotherapy. It emphasizes clinical implications inhibition on behavior neutrophils, macrophages, T cells, NK cells. explores potential antagonism combined with immunotherapeutic strategies enhance cancer treatment paradigms. discusses innovative immunotherapies targeting c-MET, chimeric antigen (CAR) therapies, monoclonal antibodies, antibody-drug conjugates, encouraging development comprehensive strategy simultaneously tackles evasion enhances anti-tumor efficacy further improve prognoses patients c-MET-positive malignancies. Despite challenges variability across different subtypes, continued research into molecular mechanisms will be crucial.

Language: Английский

Citations

1